MAP 2.94% 16.5¢ microba life sciences limited

very interesting, page-5

  1. 2,656 Posts.
    MAP has suffered due to masny reasons previously stated here.

    The fact that this company continues to deliver excellent divvies and moves forward with its business plan in these conditions bodes well for the market.

    I was very surprised that it fell below $2.40 and said it would be a buy if it got to $2.20.

    I am anticipating a 20% turn around in the short term technically and another 40% growth after EFY reporting is done and dusted.

    Airlines have started to turn and the POO and DOW influences seem to have tappered.

    I could go into this very deeply but am tired this evening. Will provide qualification to above statements in the near future.

    All the best.

    Bacchus
 
watchlist Created with Sketch. Add MAP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.